[Immunizing adult respiratory patients, shall we dance along?]

[1]  M. Ison,et al.  Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults. , 2023, The New England journal of medicine.

[2]  J. Reina,et al.  Situación actual y perspectivas de futuro de las vacunas frente al virus respiratorio sincitial , 2023, Vacunas.

[3]  C. Jiménez-Ruiz,et al.  Immunosenescence, Immune Fitness and Vaccination Schedule in the Adult Respiratory Patient , 2022, Open Respiratory Archives.

[4]  F. González-Barcala,et al.  Pertussis Vaccine in COPD and Asthma: An Old Acquaintance Is Back , 2021, Open respiratory archives.

[5]  R. Dagan,et al.  A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE). , 2021, Vaccine.

[6]  R. G. van der Most,et al.  Vaccination as a preventative measure contributing to immune fitness , 2021, NPJ vaccines.

[7]  A. Schaefer,et al.  The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70 , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  F. Martinón-Torres,et al.  Tosferina en el adulto: el enemigo visible , 2021, Archivos de Bronconeumología.

[9]  M. Blanco Aparicio,et al.  Recomendaciones SEPAR y nuevos retos sobre la vacuna contra la COVID-19 en las enfermedades respiratorias , 2021, Vacunas.

[10]  H. Bernstein,et al.  Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccines: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2019 , 2020, MMWR. Morbidity and mortality weekly report.

[11]  H. Ikematsu,et al.  Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials , 2019, Human vaccines & immunotherapeutics.

[12]  J. Soriano,et al.  Variability in adherence to clinical practice guidelines and recommendations in COPD outpatients: a multi-level, cross-sectional analysis of the EPOCONSUL study , 2017, Respiratory Research.

[13]  M. C. Rubio,et al.  Actualización 2021 de la Guía Española de la EPOC (GesEPOC). Tratamiento farmacológico de la EPOC estable , 2012, Archivos de Bronconeumología.